Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.2Last Year’s EPS
-1.44Same Quarter Last Year
Strong Buy
Based on 18 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 18, 2025
|% Change Since: -3.19%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Neutral
Axsome Therapeutics showed strong revenue growth and significant progress in its product pipeline, including new product approvals. However, the company continued to face high net losses and operating expenses, along with challenges in market access and pricing pressures. The overall sentiment of the call is optimistic about future growth, yet tempered by these financial challenges.Company Guidance
During the Axsome Therapeutics fourth quarter and full year 2024 conference call, the company provided guidance on several key metrics. Total net product revenue for 2024 was $386 million, with Auvelity contributing $291.4 million, reflecting an 89% year-over-year increase for the fourth quarter. Sunosi's net product revenue was $94.3 million for the year, growing 16% year-over-year in Q4. The company anticipates continued growth in 2025 supported by a salesforce expansion for Auvelity. They also highlighted the recent US approval of Symbravo for migraine treatment and plan to commercialize it soon. In terms of clinical progress, Axsome completed Phase 3 trials for AXS-05 in Alzheimer's disease agitation and AXS-12 for narcolepsy, with NDAs planned for the second half of 2025. They expect topline readouts from several Phase 3 trials in early 2025. The company reported a net loss of $287.2 million for 2024 and ended the year with $315.4 million in cash, sufficient to fund operations into cash flow positivity.Strong Revenue Growth
Axsome reported total net product revenue of $386 million for 2024, reflecting high double-digit year-over-year growth for Auvelity and Sunosi. Auvelity net product sales were $92.6 million for Q4, representing an 89% year-over-year growth.
Product Approvals and Pipeline Progress
Received US approval of Symbravo on January 30th as a novel oral acute treatment for migraine. Completed Phase 3 clinical programs for AXS-05 and AXS-12, with plans to submit NDAs in the second half of 2025.
Commercial Success and Expansion
For Auvelity, approximately 158,000 prescriptions were filled in Q4, representing 10% quarter-over-quarter growth. The company completed its second salesforce expansion for Auvelity to support continued growth.
Cash Position and Financial Guidance
Ended 2024 with $315.4 million in cash and cash equivalents. The company believes this is sufficient to fund operations into cash flow positivity.
---
AXSM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AXSM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 18, 2025 | $131.15 | $128.09 | -2.33% |
| Nov 12, 2024 | $90.98 | $99.49 | +9.35% |
| Aug 05, 2024 | $84.42 | $83.21 | -1.43% |
| May 06, 2024 | $74.80 | $75.94 | +1.52% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Axsome Therapeutics Inc (AXSM) report earnings?
Axsome Therapeutics Inc (AXSM) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Axsome Therapeutics Inc (AXSM) earnings time?
Axsome Therapeutics Inc (AXSM) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AXSM EPS forecast?
AXSM EPS forecast for the fiscal quarter 2025 (Q1) is -1.2.
---